Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Alexandria Hammond
WLF
Alexandria Hammond
Wolfe Research
Wall Street Analyst
★★☆☆☆
#2058
on 13Foresight · ranked by our own returns
50%
Success Rate
-7.8%
Average Return
7 of 14 calls profitable · -19.4% vs benchmark
📈 Across the calls we could measure, roughly 50% of Alexandria Hammond's ratings turned a profit when each position was held for 1 year — averaging -7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

10 Buy 1 Hold 4 Sell
Alexandria's Stock Coverage 14 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
LLY
Eli Lilly & Co
 May 21, 2026 BUY Strong Buy
-11.2% avg upside
47 analysts
$1350.00
21.44% Upside
 +8.8%
REGN
Regeneron
 May 18, 2026 BUY Strong Buy
+27.5% avg upside
57 analysts
$860.00
41.38% Upside
 -2.2%
PFE
Pfizer
 May 13, 2026 SELL Buy
+31.7% avg upside
45 analysts
$26.00
0.26% Upside
 -0.1%
ABBV
AbbVie
 Jan 08, 2026 HOLD Buy
+1.3% avg upside
43 analysts
 — +0.3%
MRK
Merck & Company
 Jan 08, 2026 BUY Strong Buy
+9.8% avg upside
43 analysts
$135.00
17.03% Upside
 +4.3%
MRNA
Moderna
 Nov 20, 2025 SELL Hold
+9.4% avg upside
38 analysts
$17.00
72.40% Downside
 -128.0%
JNJ
Johnson & Johnson
 Oct 15, 2025 BUY Strong Buy
-5.2% avg upside
36 analysts
$225.00
3.95% Downside
 +25.2%
BMRN
BioMarin Pharmaceutical
 Jul 15, 2025 BUY Strong Buy
+71.7% avg upside
52 analysts
$95.00
72.61% Upside
 -2.8%
GILD
Gilead Sciences
 Dec 10, 2024 BUY Strong Buy
-5.6% avg upside
66 analysts
$109.00
13.11% Downside
 +35.3%
BMY
Bristol-Myers Squibb
 Nov 14, 2024 HOLD Buy
+7.4% avg upside
42 analysts
 — -16.3%
BIIB
Biogen
 Nov 14, 2024 HOLD Strong Buy
+24.4% avg upside
51 analysts
 — +1.6%
AMGN
Amgen
 Nov 14, 2024 HOLD Buy
-12.2% avg upside
57 analysts
 — +17.6%
MDGL
Madrigal Pharmaceuticals
 Aug 07, 2024 SELL Strong Buy
-4.7% avg upside
31 analysts
$150.00
70.09% Downside
 -46.2%
VRTX
Vertex Pharmaceuticals
 Aug 02, 2024 BUY Strong Buy
-3.9% avg upside
61 analysts
$550.00
19.92% Upside
 -6.5%
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Alexandria Hammond — Frequently Asked Questions
How accurate are Alexandria Hammond's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Alexandria's ratings were profitable over a one-year hold, with an average return of -7.8% per rating, or -19.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Alexandria ranked on 13Foresight?
Alexandria Hammond is currently ranked #2058 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Alexandria cover?
Alexandria most recently has ratings on LLY, REGN, PFE, ABBV, MRK, MRNA, JNJ, BMRN, GILD, BMY, BIIB, AMGN and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.